Cigna Profits Hit $1.5 Billion Despite Higher Costs

Cigna Group reported a Q2 2025 net income of $1.5 billion ($5.71/share) and an 11% revenue increase to $67.2 billion, with adjusted income from operations up 1%. This performance was primarily driven by robust growth in its Evernorth health services segment, which saw strong specialty pharmacy growth and increased client relationships. However, profitability was partially offset by rising "stop loss medical costs" within its Cigna Healthcare employer benefits business, elevating the medical cost ratio to 83.2%. Despite these cost pressures, Cigna reaffirmed its 2025 adjusted income from operations outlook of at least $29.60 per share, signaling confidence in its business mix.

Analysis

The Cigna Group demonstrated a resilient but mixed performance in its second quarter 2025 results, characterized by strong top-line growth offset by margin pressure in its core insurance business. Total revenues grew a significant 11% year-over-year to $67.2 billion, while net income remained flat at $1.5 billion. The primary growth engine was the Evernorth Health Services segment, which benefited from strong specialty pharmacy growth and expanded client relationships, leading to a 3% increase in total pharmacy customers to 121.9 million since the end of 2024. This strength was counterbalanced by challenges in the Cigna Healthcare segment, where higher-than-expected "stop loss medical costs" caused the medical cost ratio to deteriorate to 83.2% from 82.3% in the prior year. Notably, these cost pressures are distinct from the Medicare Advantage headwinds affecting industry rivals, a direct consequence of Cigna's strategic divestiture of its Medicare businesses. Despite the margin compression, management conveyed confidence by reaffirming its full-year 2025 guidance for adjusted income from operations of "at least $29.60 per share," signaling a belief that the strength of its business mix, led by Evernorth, can absorb the current cost challenges.

Key Decisions for Investors

• Investors should weigh the robust 11% revenue growth and reaffirmed full-year earnings guidance against the evident margin pressure in the Cigna Healthcare segment.
• It is critical to monitor the medical cost ratio and any future disclosures on 'stop loss' claims, as this metric is a key indicator of profitability trends for the insurer.
• Consider the successful strategic pivot away from the Medicare business, which has insulated Cigna from certain industry-wide headwinds and sharpened its focus on the high-growth Evernorth pharmacy services platform.